Andrea Igoren Guaricci

Impact of GLP1Ra and SGLT2i on atrial fibrillation in overweight, non-diabetic patients: A meta-analysis of randomized evidence

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1Ra) are breakthrough therapies for type 2 diabetes (T2DM), exhibiting pleiotropic effects. Their clinical use has expanded to lower-risk populations, including overweight and ob...